SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-005058
Filing Date
2022-01-10
Accepted
2022-01-10 07:19:02
Documents
14
Period of Report
2022-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d272571d8k.htm   iXBRL 8-K 23770
2 EX-99.1 d272571dex991.htm EX-99.1 50358
6 GRAPHIC g272571ex99logo.jpg GRAPHIC 4659
  Complete submission text file 0001193125-22-005058.txt   214599

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20220110.xsd EX-101.SCH 2886
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20220110_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20220110_pre.xml EX-101.PRE 11404
8 EXTRACTED XBRL INSTANCE DOCUMENT d272571d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 22519672
SIC: 2834 Pharmaceutical Preparations